# Sunrun Inc.: financial statements, quarterly

RUN · Nasdaq · CIK 1469367 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/run.md) · [Financials](/companies/run/financials.md) · [Filings](/companies/run/filings.md) · [Insiders](/companies/run/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/run/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [563](/filings/0001469367-24-000199.md) | [517 d](/filings/0001628280-26-012289.md) | [458](/filings/0001469367-25-000104.md) | [524](/filings/0001469367-25-000148.md) | [537](/filings/0001628280-25-050191.md) | [518 d](/filings/0001628280-26-012289.md) | [504](/filings/0001628280-26-031271.md) | [569](/filings/0001628280-26-053366.md) | [725](/filings/0001628280-25-050191.md) | [1,159 d](/filings/0001628280-26-012289.md) | [722](/filings/0001628280-26-031271.md) | [870](/filings/0001628280-26-053366.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.0](/filings/0001469367-24-000199.md) | [7.7 d](/filings/0001628280-26-012289.md) | [12.1](/filings/0001469367-25-000104.md) | [10.2](/filings/0001469367-25-000148.md) | [8.2](/filings/0001628280-25-050191.md) | [8.8 d](/filings/0001628280-26-012289.md) | [10.0](/filings/0001628280-26-031271.md) | [8.1](/filings/0001628280-26-053366.md) | [9.3](/filings/0001628280-25-050191.md) | [8.8 d](/filings/0001628280-26-012289.md) | [10.1](/filings/0001628280-26-031271.md) | [10.2](/filings/0001628280-26-053366.md) |
| Operating income | $m | [(1,347)](/filings/0001469367-24-000199.md) | [(198) d](/filings/0001628280-26-012289.md) | [(183)](/filings/0001469367-25-000104.md) | [(128)](/filings/0001469367-25-000148.md) | [(128)](/filings/0001628280-25-050191.md) | [(3,256) d](/filings/0001628280-26-012289.md) | [(115)](/filings/0001628280-26-031271.md) | [(112)](/filings/0001628280-26-053366.md) | [3.7](/filings/0001628280-25-050191.md) | [97.4 d](/filings/0001628280-26-012289.md) | [(43.5)](/filings/0001628280-26-031271.md) | [34.8](/filings/0001628280-26-053366.md) |
| Interest expense | $m | [171](/filings/0001469367-24-000199.md) | not reported | not reported | [207](/filings/0001469367-24-000146.md) | [216](/filings/0001469367-24-000199.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [29.8](/filings/0001469367-24-000199.md) | [(1.6) d](/filings/0001628280-26-012289.md) | [(2.2)](/filings/0001469367-25-000104.md) | [(10.9)](/filings/0001469367-25-000148.md) | [(13.8)](/filings/0001628280-25-050191.md) | [0.1 d](/filings/0001628280-26-012289.md) | [(111)](/filings/0001628280-26-031271.md) | [(94.9)](/filings/0001628280-26-053366.md) | [(2.2)](/filings/0001628280-25-050191.md) | [40.4 d](/filings/0001628280-26-012289.md) | [7.1](/filings/0001628280-26-031271.md) | [(4.0)](/filings/0001628280-26-053366.md) |
| Net income | $m | [(1,069)](/filings/0001469367-24-000199.md) | [(350) d](/filings/0001628280-26-012289.md) | [(87.8)](/filings/0001469367-25-000104.md) | [139](/filings/0001469367-25-000148.md) | [(83.8)](/filings/0001628280-25-050191.md) | [(2,814) d](/filings/0001628280-26-012289.md) | [50.0](/filings/0001628280-26-031271.md) | [280](/filings/0001628280-26-053366.md) | [16.6](/filings/0001628280-25-050191.md) | [104 d](/filings/0001628280-26-012289.md) | [168](/filings/0001628280-26-031271.md) | [115](/filings/0001628280-26-053366.md) |
| Diluted EPS | $ per share | [(4.92)](/filings/0001469367-24-000199.md) | not reported | [(0.40)](/filings/0001469367-25-000104.md) | [0.55](/filings/0001469367-25-000148.md) | [(0.37)](/filings/0001628280-25-050191.md) | not reported | [0.20](/filings/0001628280-26-031271.md) | [1.07](/filings/0001628280-26-053366.md) | [0.06](/filings/0001628280-25-050191.md) | not reported | [0.62](/filings/0001628280-26-031271.md) | [0.42](/filings/0001628280-26-053366.md) |
| Basic EPS | $ per share | [(4.92)](/filings/0001469367-24-000199.md) | not reported | [(0.40)](/filings/0001469367-25-000104.md) | [0.63](/filings/0001469367-25-000148.md) | [(0.37)](/filings/0001628280-25-050191.md) | not reported | [0.22](/filings/0001628280-26-031271.md) | [1.22](/filings/0001628280-26-053366.md) | [0.07](/filings/0001628280-25-050191.md) | not reported | [0.71](/filings/0001628280-26-031271.md) | [0.48](/filings/0001628280-26-053366.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.6](/filings/0001469367-24-000199.md) | [0.7](/filings/0001628280-26-012289.md) | [0.5](/filings/0001469367-25-000104.md) | [0.7](/filings/0001469367-25-000148.md) | [0.5](/filings/0001628280-25-050191.md) | [0.6](/filings/0001628280-26-053366.md) | [0.6](/filings/0001628280-26-031271.md) | [0.6](/filings/0001628280-26-053366.md) | [0.7](/filings/0001628280-25-050191.md) | [0.8](/filings/0001628280-26-053366.md) | [0.7](/filings/0001628280-26-031271.md) | [0.7](/filings/0001628280-26-053366.md) |
| Current assets | $bn | [1.9](/filings/0001469367-23-000202.md) | [1.9](/filings/0001469367-25-000039.md) | [1.7](/filings/0001469367-24-000092.md) | [1.7](/filings/0001469367-24-000146.md) | [1.6](/filings/0001469367-24-000199.md) | [1.7](/filings/0001628280-26-012289.md) | [1.7](/filings/0001469367-25-000104.md) | [1.8](/filings/0001469367-25-000148.md) | [2.1](/filings/0001628280-25-050191.md) | [2.2](/filings/0001628280-26-053366.md) | [2.0](/filings/0001628280-26-031271.md) | [2.2](/filings/0001628280-26-053366.md) |
| Total assets | $bn | [20.0](/filings/0001469367-23-000202.md) | [20.5](/filings/0001469367-25-000039.md) | [20.8](/filings/0001469367-24-000092.md) | [21.4](/filings/0001469367-24-000146.md) | [22.1](/filings/0001469367-24-000199.md) | [19.9](/filings/0001628280-26-012289.md) | [20.4](/filings/0001469367-25-000104.md) | [21.2](/filings/0001469367-25-000148.md) | [22.2](/filings/0001628280-25-050191.md) | [22.6](/filings/0001628280-26-053366.md) | [22.8](/filings/0001628280-26-031271.md) | [23.4](/filings/0001628280-26-053366.md) |
| Current liabilities | $bn | [1.4](/filings/0001469367-23-000202.md) | [1.5](/filings/0001469367-25-000039.md) | [1.3](/filings/0001469367-24-000092.md) | [1.0](/filings/0001469367-24-000146.md) | [1.1](/filings/0001469367-24-000199.md) | [1.3](/filings/0001628280-26-012289.md) | [1.3](/filings/0001469367-25-000104.md) | [1.3](/filings/0001469367-25-000148.md) | [1.4](/filings/0001628280-25-050191.md) | [1.3](/filings/0001628280-26-053366.md) | [1.4](/filings/0001628280-26-031271.md) | [1.5](/filings/0001628280-26-053366.md) |
| Total liabilities | $bn | [13.0](/filings/0001469367-23-000202.md) | [13.5](/filings/0001469367-25-000039.md) | [14.1](/filings/0001469367-24-000092.md) | [14.4](/filings/0001469367-24-000146.md) | [15.1](/filings/0001469367-24-000199.md) | [15.7](/filings/0001628280-26-012289.md) | [16.3](/filings/0001469367-25-000104.md) | [16.8](/filings/0001469367-25-000148.md) | [17.6](/filings/0001628280-25-050191.md) | [17.6](/filings/0001628280-26-053366.md) | [17.8](/filings/0001628280-26-031271.md) | [18.2](/filings/0001628280-26-053366.md) |
| Long-term debt | $bn | [10.2](/filings/0001469367-23-000202.md) | [10.7](/filings/0001469367-25-000039.md) | [11.1](/filings/0001469367-24-000092.md) | [12.0](/filings/0001469367-24-000146.md) | [12.5](/filings/0001469367-24-000199.md) | [12.9](/filings/0001628280-26-012289.md) | [13.6](/filings/0001469367-25-000104.md) | [14.0](/filings/0001469367-25-000148.md) | [14.6](/filings/0001628280-25-050191.md) | [14.7](/filings/0001628280-26-053366.md) | [14.8](/filings/0001628280-26-031271.md) | [15.2](/filings/0001628280-26-053366.md) |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [5.6](/filings/0001469367-23-000202.md) | [5.2](/filings/0001469367-25-000039.md) | [5.2](/filings/0001469367-24-000092.md) | [5.4](/filings/0001469367-24-000146.md) | [5.3](/filings/0001469367-24-000199.md) | [2.6](/filings/0001628280-26-012289.md) | [2.6](/filings/0001469367-25-000104.md) | [2.9](/filings/0001469367-25-000148.md) | [3.0](/filings/0001628280-25-050191.md) | [3.1](/filings/0001628280-26-053366.md) | [3.3](/filings/0001628280-26-031271.md) | [3.5](/filings/0001628280-26-053366.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(63.2) d](/filings/0001469367-24-000199.md) | [(116) d](/filings/0001628280-26-012289.md) | [(143)](/filings/0001469367-25-000104.md) | [(209) d](/filings/0001469367-25-000148.md) | [(156) d](/filings/0001628280-25-050191.md) | [(258) d](/filings/0001628280-26-012289.md) | [(104)](/filings/0001628280-26-031271.md) | [(293) d](/filings/0001628280-26-053366.md) | [(122) d](/filings/0001628280-25-050191.md) | [96.9 d](/filings/0001628280-26-012289.md) | [10.6](/filings/0001628280-26-031271.md) | [(186) d](/filings/0001628280-26-053366.md) |
| Capital expenditure | $m | [4.7 d](/filings/0001469367-24-000199.md) | [4.7 d](/filings/0001469367-25-000039.md) | not reported | not reported | [0.2 d](/filings/0001469367-24-000199.md) | [0.6 d](/filings/0001469367-25-000039.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [221](/filings/0001469367-23-000202.md) | [215](/filings/0001469367-24-000092.md) | [222](/filings/0001469367-24-000146.md) | [217](/filings/0001469367-24-000199.md) | [220](/filings/0001469367-25-000104.md) | [255](/filings/0001469367-25-000148.md) | [224](/filings/0001628280-25-050191.md) | [258](/filings/0001628280-26-031271.md) | [261](/filings/0001628280-26-053366.md) | [267](/filings/0001628280-25-050191.md) | [272](/filings/0001628280-26-031271.md) | [274](/filings/0001628280-26-053366.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 240,846,982 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053366.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.